Figure 1.

Effects of different concentrations of irreversible BTKi’s on platelet aggregation in blood after FcγRIIA stimulation by cross-linking. Blood samples were preincubated for 60 minutes with solvent (DMSO, 0.1%) or BTKi’s (ibrutinib, acalabrutinib, tirabrutinib, zanubrutinib, or evobrutinib) before incubation for 3 minutes with the mouse anti-CD32 antibody AT10 (2 µg/mL) and subsequent cross-linking with Fab2 of anti-mouse IgG (30 µg/mL) for 10 minutes. Values are mean ± standard deviation (SD) (n = 6). **P < .01; ***P < .001; ⁺⁺⁺P < .001.